Kenvue Inc trades at $19.24 with a distinctive defensive profile characterized by a beta of 0.45, positioning the consumer products firm as a lower-volatility holding during market turbulence. The company's market capitalization of $36.9B reflects its scale in personal care and over-the-counter health products, though systematic screening highlights notable divergence between growth metrics and valuation multiples.

The fundamental model indicates several structural strengths:

• Gross margin of 58.85% demonstrates strong brand pricing power and product differentiation in competitive consumer categories
• Return on equity of 15.18% exceeds cost of capital thresholds typically applied in consumer staples analysis
• EPS expansion of 53.73% year-over-year signals operational efficiency gains, contrasting sharply with revenue contraction of -0.07%
• Net margin of 10.61% reflects disciplined cost management despite flat top-line performance

Risk factors warrant attention in quantitative frameworks. The current ratio of 0.96 falls below the 1.0 threshold, potentially constraining short-term financial flexibility. Revenue decline, though marginal, raises questions about organic growth trajectory in a post-spin environment. The P/E ratio of 22.86 commands a premium valuation despite near-zero revenue growth, suggesting the market prices in future margin expansion rather than volume acceleration.

Relative to peers including Estée Lauder (EL), e.l.f. Beauty (ELF), and Inter Parfums (IPAR), Kenvue operates with lower beta exposure and higher gross margins, though peer comparison reveals divergent growth dynamics. The debt-to-equity ratio of 0.79 positions the balance sheet within moderate leverage parameters for the sector.